-

Viz.ai Launches Viz 3D CTA™ to Deliver Enhanced Imaging and Accelerate Clinical Decision-Making

New feature provides AI-enhanced 3D imaging to improve neurovascular visualization and streamline workflows

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz 3D CTA, a new solution that automatically converts computed tomography angiography (CTA) scans into high-resolution, AI-enhanced 3D images for faster and clearer neurovascular visualization. Fully integrated into the Viz.ai platform, this capability enables care teams to interact with complex neurovascular anatomy in real-time — automatically removing bone and venous structures to enhance clarity and support time savings in stroke and aneurysm workflows.

“Viz 3D CTA gives me a clearer, faster view of what’s going on. Being able to rotate the image and see vessels from different angles makes a big difference, especially in tricky areas,” said Benjamin Alwood, MD, neurologist at UF Health Jacksonville. “It’s also a great safety net for spotting occlusions that might otherwise be missed. Having this kind of clarity right away helps me make quicker, more confident decisions.”

Viz 3D CTA addresses challenges in neurovascular imaging, including delays due to manual 3D renderings, limited spatial context in PACS, and difficulty viewing smaller or more distal vessel abnormalities. With automated post-processing, skull-stripped views, and interactive tools — including sagittal and axial rotation — Viz 3D CTA offers clinicians a dynamic, full-brain perspective within minutes.

“With Viz 3D CTA, we’re extending the Viz.ai One® platform with a powerful imaging tool that enables clearer, faster decisions in neurovascular care,” said Prem Batchu-Green, VP of Care Pathways, Value and Success at Viz.ai. “We are proud to bring this capability directly into the hands of providers who are working to save lives and preserve function every day.”

Viz 3D CTA is now available to hospitals and health systems on the Viz.ai One platform, which is deployed in over 1,700 hospitals and health systems. To learn more about Viz 3D CTA, visit viz.ai/neuro.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.

Contacts

Media Contacts
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Viz.ai, Inc.


Release Versions

Contacts

Media Contacts
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Social Media Profiles
More News From Viz.ai, Inc.

A Decade of Increasing Access to Life Saving Treatments: Viz.ai Celebrates 10 Years, 2,000 Hospitals, and 230 Million Patients

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today celebrates its 10th anniversary, marking a decade of transforming how healthcare teams deliver care for patients. The company launched in 2016 to solve a key problem: variability in healthcare means that many patients fail to get guideline based care, even in life threatening diseases like stroke. Since achieving the first FDA clearance for an AI platform and increasing tr...

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to pote...

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growi...
Back to Newsroom